vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
LiveRamp Holdings, Inc. is the larger business by last-quarter revenue ($212.2M vs $180.9M, roughly 1.2× AVANOS MEDICAL, INC.). LiveRamp Holdings, Inc. runs the higher net margin — 18.8% vs -0.7%, a 19.5% gap on every dollar of revenue. On growth, LiveRamp Holdings, Inc. posted the faster year-over-year revenue change (8.6% vs 0.7%). Over the past eight quarters, LiveRamp Holdings, Inc.'s revenue compounded faster (11.1% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
AVNS vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $212.2M |
| Net Profit | $-1.3M | $39.9M |
| Gross Margin | 47.5% | 71.9% |
| Operating Margin | 1.4% | 18.6% |
| Net Margin | -0.7% | 18.8% |
| Revenue YoY | 0.7% | 8.6% |
| Net Profit YoY | 99.7% | 255.7% |
| EPS (diluted) | $-0.02 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $212.2M | ||
| Q3 25 | $177.8M | $199.8M | ||
| Q2 25 | $175.0M | $194.8M | ||
| Q1 25 | $167.5M | $188.7M | ||
| Q4 24 | $179.6M | $195.4M | ||
| Q3 24 | $170.4M | $185.5M | ||
| Q2 24 | $171.7M | $176.0M | ||
| Q1 24 | $166.1M | $171.9M |
| Q4 25 | $-1.3M | $39.9M | ||
| Q3 25 | $-1.4M | $27.4M | ||
| Q2 25 | $-76.8M | $7.7M | ||
| Q1 25 | $6.6M | $-6.3M | ||
| Q4 24 | $-397.3M | $11.2M | ||
| Q3 24 | $4.3M | $1.7M | ||
| Q2 24 | $1.8M | $-7.5M | ||
| Q1 24 | $-900.0K | $-5.4M |
| Q4 25 | 47.5% | 71.9% | ||
| Q3 25 | 48.4% | 70.2% | ||
| Q2 25 | 52.6% | 70.1% | ||
| Q1 25 | 53.6% | 69.3% | ||
| Q4 24 | 54.6% | 71.9% | ||
| Q3 24 | 54.5% | 72.4% | ||
| Q2 24 | 55.7% | 70.6% | ||
| Q1 24 | 57.1% | 72.2% |
| Q4 25 | 1.4% | 18.6% | ||
| Q3 25 | 0.1% | 10.7% | ||
| Q2 25 | -42.6% | 3.7% | ||
| Q1 25 | 6.1% | -6.1% | ||
| Q4 24 | -233.0% | 7.5% | ||
| Q3 24 | 7.0% | 4.0% | ||
| Q2 24 | 3.7% | -3.0% | ||
| Q1 24 | 2.4% | -8.3% |
| Q4 25 | -0.7% | 18.8% | ||
| Q3 25 | -0.8% | 13.7% | ||
| Q2 25 | -43.9% | 4.0% | ||
| Q1 25 | 3.9% | -3.3% | ||
| Q4 24 | -221.2% | 5.7% | ||
| Q3 24 | 2.5% | 0.9% | ||
| Q2 24 | 1.0% | -4.3% | ||
| Q1 24 | -0.5% | -3.1% |
| Q4 25 | $-0.02 | $0.62 | ||
| Q3 25 | $-0.03 | $0.42 | ||
| Q2 25 | $-1.66 | $0.12 | ||
| Q1 25 | $0.14 | $-0.10 | ||
| Q4 24 | $-8.64 | $0.17 | ||
| Q3 24 | $0.09 | $0.03 | ||
| Q2 24 | $0.04 | $-0.11 | ||
| Q1 24 | $-0.02 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $403.4M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $962.3M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $403.4M | ||
| Q3 25 | $70.5M | $376.9M | ||
| Q2 25 | $90.3M | $371.1M | ||
| Q1 25 | $97.0M | $420.8M | ||
| Q4 24 | $107.7M | $384.3M | ||
| Q3 24 | $89.0M | $348.4M | ||
| Q2 24 | $92.2M | $342.7M | ||
| Q1 24 | $75.8M | $368.9M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $962.3M | ||
| Q3 25 | $778.0M | $943.8M | ||
| Q2 25 | $776.3M | $947.8M | ||
| Q1 25 | $839.4M | $948.9M | ||
| Q4 24 | $828.5M | $957.7M | ||
| Q3 24 | $1.2B | $932.1M | ||
| Q2 24 | $1.2B | $951.9M | ||
| Q1 24 | $1.2B | $949.1M |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.7B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | — | ||
| Q3 25 | $14.0M | $57.4M | ||
| Q2 25 | $6.8M | $-15.8M | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | $45.1M | ||
| Q3 24 | $23.0M | $55.6M | ||
| Q2 24 | $27.8M | $-9.3M | ||
| Q1 24 | $-8.0M | — |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | $56.8M | ||
| Q2 25 | $-4.2M | $-16.2M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | $44.8M | ||
| Q3 24 | $20.0M | $55.4M | ||
| Q2 24 | $21.9M | $-9.6M | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | 28.4% | ||
| Q2 25 | -2.4% | -8.3% | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | 22.9% | ||
| Q3 24 | 11.7% | 29.8% | ||
| Q2 24 | 12.8% | -5.4% | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 6.3% | 0.2% | ||
| Q1 25 | 4.0% | 0.2% | ||
| Q4 24 | 2.7% | 0.1% | ||
| Q3 24 | 1.8% | 0.1% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | 5.35× | 32.10× | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RAMP
Segment breakdown not available.
